SUMMIT, N.J., Feb. 6, 2008 (PRIME NEWSWIRE) -- CorMedix Inc., a New York-area biopharmaceutical company, announced today that it had acquired exclusive worldwide rights to develop, manufacture and market Neutrolin(r), a liquid that "locks" a patient's central venous catheter (CVC) between hemodialysis (HD) sessions to keep it free of infection and clots.
"We hope Neutrolin(r) will be a paradigm-changing weapon in fighting one of the single greatest causes of morbidity and mortality among the 300,000 kidney failure patients in the U.S. who undergo life-sustaining HD treatments," said Bruce Cooper, M.D., President and Chief Executive Officer of CorMedix.
More than 25 percent of HD patients rely on a CVC for vascular access. Recent estimates suggest that up to 160,000 new cases of catheter-related blood stream infection (CRBSI) emerge each year in HD alone. At best, these infections result in the need for antibiotics; at worst, they result in catheter replacement, hospitalization and possibly premature death. (American Journal of Kidney Diseases 51 (2) 2008: pp. 165-168)
full article >> http://www.primenewswire.com/newsroom/news.html?d=135819
Wednesday, February 6, 2008
CorMedix Licenses New Technology to Prevent Infection and Clots in Central Venous Catheters
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment